stocks logo

CDMO Valuation

Avid Bioservices Inc
$
12.490
0(0.000%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings

CDMO Relative Valuation

CDMO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CDMO is overvalued; if below, it's undervalued.

Historical Valuation

Avid Bioservices Inc (CDMO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.57 is considered Undervalued compared with the five-year average of 52.11. The fair price of Avid Bioservices Inc (CDMO) is between 29.16 to 44.16 according to relative valuation methord. Compared to the current price of 12.49 USD , Avid Bioservices Inc is Undervalued By 57.17%.
Relative Value
Fair Zone
29.16-44.16
Current Price:12.49
57.17%
Undervalued
-69.39
PE
1Y
3Y
5Y
Trailing
Forward
49.24
EV/EBITDA
Avid Bioservices Inc. (CDMO) has a current EV/EBITDA of 49.24. The 5-year average EV/EBITDA is 83.86. The thresholds are as follows: Strongly Undervalued below -172.41, Undervalued between -172.41 and -44.27, Fairly Valued between 212.00 and -44.27, Overvalued between 212.00 and 340.14, and Strongly Overvalued above 340.14. The current Forward EV/EBITDA of 49.24 falls within the Historic Trend Line -Fairly Valued range.
-141.07
EV/EBIT
Avid Bioservices Inc. (CDMO) has a current EV/EBIT of -141.07. The 5-year average EV/EBIT is -71.85. The thresholds are as follows: Strongly Undervalued below -854.24, Undervalued between -854.24 and -463.05, Fairly Valued between 319.35 and -463.05, Overvalued between 319.35 and 710.55, and Strongly Overvalued above 710.55. The current Forward EV/EBIT of -141.07 falls within the Historic Trend Line -Fairly Valued range.
4.57
PS
Avid Bioservices Inc. (CDMO) has a current PS of 4.57. The 5-year average PS is 6.89. The thresholds are as follows: Strongly Undervalued below 0.03, Undervalued between 0.03 and 3.46, Fairly Valued between 10.32 and 3.46, Overvalued between 10.32 and 13.75, and Strongly Overvalued above 13.75. The current Forward PS of 4.57 falls within the Historic Trend Line -Fairly Valued range.
105.12
P/OCF
Avid Bioservices Inc. (CDMO) has a current P/OCF of 105.12. The 5-year average P/OCF is 92.89. The thresholds are as follows: Strongly Undervalued below -130.83, Undervalued between -130.83 and -18.97, Fairly Valued between 204.75 and -18.97, Overvalued between 204.75 and 316.60, and Strongly Overvalued above 316.60. The current Forward P/OCF of 105.12 falls within the Historic Trend Line -Fairly Valued range.
446.56
P/FCF
Avid Bioservices Inc. (CDMO) has a current P/FCF of 446.56. The 5-year average P/FCF is 14.73. The thresholds are as follows: Strongly Undervalued below -521.21, Undervalued between -521.21 and -253.24, Fairly Valued between 282.70 and -253.24, Overvalued between 282.70 and 550.66, and Strongly Overvalued above 550.66. The current Forward P/FCF of 446.56 falls within the Overvalued range.
Avid Bioservices Inc (CDMO) has a current Price-to-Book (P/B) ratio of 17.83. Compared to its 3-year average P/B ratio of 6.65 , the current P/B ratio is approximately 168.13% higher. Relative to its 5-year average P/B ratio of 11.80, the current P/B ratio is about 51.10% higher. Avid Bioservices Inc (CDMO) has a Forward Free Cash Flow (FCF) yield of approximately -1.21%. Compared to its 3-year average FCF yield of -7.77%, the current FCF yield is approximately -84.40% lower. Relative to its 5-year average FCF yield of -4.37% , the current FCF yield is about -72.25% lower.
17.83
P/B
Median3y
6.65
Median5y
11.80
-1.21
FCF Yield
Median3y
-7.77
Median5y
-4.37

Competitors Valuation Multiple

The average P/S ratio for CDMO's competitors is 34.37, providing a benchmark for relative valuation. Avid Bioservices Inc Corp (CDMO) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 31.84%, this premium appears sustainable.

Performance Decomposition

1Y
3Y
5Y
Market capitalization of CDMO increased by 19.64% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -37.44 to -51.99.
The secondary factor is the Revenue Growth, contributed 31.84%to the performance.
Overall, the performance of CDMO in the past 1 year is driven by Margin Expansion. Which is more sustainable.
31.84%
25.40M → 33.48M
Revenue Growth
+
38.86%
-37.44 → -51.99
Margin Expansion
+
-51.06%
-10.66 → -5.22
P/E Change
=
19.64%
10.44 → 12.49
Mkt Cap Growth

FAQ

arrow icon

Is Avid Bioservices Inc (CDMO) currently overvalued or undervalued?

Avid Bioservices Inc (CDMO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.57 is considered Undervalued compared with the five-year average of 52.11. The fair price of Avid Bioservices Inc (CDMO) is between 29.16 to 44.16 according to relative valuation methord. Compared to the current price of 12.49 USD , Avid Bioservices Inc is Undervalued By 57.17% .
arrow icon

What is Avid Bioservices Inc (CDMO) fair value?

arrow icon

How does CDMO's valuation metrics compare to the industry average?

arrow icon

What is the current P/B ratio for Avid Bioservices Inc (CDMO) as of Jul 28 2025?

arrow icon

What is the current FCF Yield for Avid Bioservices Inc (CDMO) as of Jul 28 2025?

arrow icon

What is the current Forward P/E ratio for Avid Bioservices Inc (CDMO) as of Jul 28 2025?

arrow icon

What is the current Forward P/S ratio for Avid Bioservices Inc (CDMO) as of Jul 28 2025?